Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced a Research Forum to showcase its pipeline of next-generation ADCs. The event is scheduled for October 10, 2024, at 1:30 p.m. PT / 4:30 p.m. ET and will be accessible via live webcast.

Investors and interested parties can join the presentation by visiting https://ir.sutrobio.com/news-events/ir-calendar. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.

This forum represents an opportunity for Sutro Biopharma to highlight its innovative approach to ADC development and provide insights into its near-term pipeline, potentially impacting investor interest and the company's stock performance.

News Market Reaction

+4.30%

1 alert

+4.30% News Effect

On the day this news was published, STRO gained 4.30%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.

Webcast Information:
To access the live audio webcast on Thursday, October 10, at 1:30 p.m. PT / 4:30 p.m. ET, please go to https://ir.sutrobio.com/news-events/ir-calendar

An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

FAQ

When is Sutro Biopharma (STRO) hosting its Research Forum on next-generation ADCs?

Sutro Biopharma (STRO) is hosting its Research Forum on next-generation ADCs on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access Sutro Biopharma's (STRO) Research Forum webcast?

Investors can access Sutro Biopharma's (STRO) Research Forum webcast by visiting https://ir.sutrobio.com/news-events/ir-calendar on October 10, 2024, at the scheduled time.

What will Sutro Biopharma (STRO) discuss during its October 2024 Research Forum?

Sutro Biopharma (STRO) will highlight its pipeline of next-generation antibody drug conjugates (ADCs) and discuss near-term pipeline developments during its October 2024 Research Forum.

Will there be a replay available for Sutro Biopharma's (STRO) October 2024 Research Forum?

Yes, an archived replay of Sutro Biopharma's (STRO) October 2024 Research Forum webcast will be available on the company's website following the live presentation.